Výsledky vyhledávání - "Nadja E. Schoemaker"

Phase I study of an oral formulation of irinotecan administered daily for 14�days every 3�weeks in patients with advanced solid tumours

Autor: Isa E.L.M. Kuppens, Nadja E. Schoemaker, Patricia Lefebvre, Ger-Jan Sanderink, Wim W. ten Bokkel Huinink, Jan H.M. Schellens, Sylvie Assadourian, Jos H. Beijnen

Publikováno v: Cancer Chemotherapy and Pharmacology. 55:263-270

A phase I study was conducted with oral irinotecan given daily for 14 days every 3 weeks in 45 patients with solid tumours to establish the maximum tolerated dose (MTD), toxicity, preliminary antitumour response and pharmacokinetics. Irinotecan was a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f117bdc4e7cca3f9498033525a97cad8
https://doi.org/10.1007/s00280-004-0874-2

Zobrazit plný text záznamu

A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin

Autor: Nadja E. Schoemaker, Sindy Jansen, Jan Lieverst, R Spinelli, Massimo Breda, M. Swart, C Pellizzoni, Hilde Rosing, C. van Kesteren, D Fraier, M Grazia Porro, W.W. ten Bokkel Huinink, Jos H. Beijnen, Jan H.M. Schellens

Publikováno v: British Journal of Cancer

Polymeric drug conjugates are a new and experimental class of drug delivery systems with pharmacokinetic promises. The antineoplastic drug camptothecin was linked to a water-soluble polymeric backbone (MAG-CPT) and administrated as a 30 min infusion

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::737b15ea111b1066a21a178880c9c4b9
https://doi.org/10.1038/sj.bjc.6600516

Zobrazit plný text záznamu

Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer

Autor: Mirjam, Crul, Nadja E, Schoemaker, Dick, Pluim, Marc, Maliepaard, René W M, Underberg, Margaret, Schot, Rolf W, Sparidans, Paul, Baas, Jos H, Beijnen, Nico, Van Zandwijk, Jan H M, Schellens

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 9(10 Pt 1)

To establish the maximum dose intensity of cisplatin plus gemcitabine on a weekly or two-weekly schedule in patients with advanced non-small cell lung cancer (NSCLC).Patients with NSCLC stage IIIB or IV were randomized to receive weekly or two-weekly

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::56f0f680a81ede87b178b3bda5972593
https://pubmed.ncbi.nlm.nih.gov/14506138

Zobrazit plný text záznamu

Determination of 9-nitrocamptothecin and its metabolite 9-aminocamptothecin in human plasma using high-performance liquid chromatography with ultraviolet and fluorescence detection

Autor: Patrick Schöffski, Jos H. Beijnen, Jinee Rizzo, Jan H.M. Schellens, Sindy Jansen, Hilde Rosing, Nadja E. Schoemaker

Publikováno v: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 775(2)

A high-performance liquid chromatography assay is described for the determination of the investigational anti-cancer drug 9-nitrocamptothecin (9-NC) and its metabolite 9-aminocamptothecin (9-AC) as the total of their lactone and carboxylate forms. Th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da5f53a4bd78c8b683fb034d994c1e23
https://pubmed.ncbi.nlm.nih.gov/12113990

Zobrazit plný text záznamu

Topoisomerase I levels in white blood cells of patients with ovarian cancer treated with paclitaxel-cisplatin-topotecan in a phase I study

Autor: Jan H.M. Schellens, V. M. M. Herben, Robert C.A.M. van Waardenburg, Jos H. Beijnen, Dick Pluim, Laurina A. de Jong, Nadja E. Schoemaker, Wim W. ten Bokkel Huinink

Publikováno v: Anti-cancer drugs. 13(1)

Topotecan stabilizes the topoisomerase I (Topo I) cleavable complex. We measured Topo I levels in white blood cells of patients with ovarian cancer treated with topotecan. Topotecan was given i.v. daily x 5 q 3 weeks in combination with paclitaxel (1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e25f6a5e40c86cde287e2f3b72c2731f
https://pubmed.ncbi.nlm.nih.gov/11914645

Zobrazit plný text záznamu

Urinary and fecal excretion of topotecan in patients with malignant solid tumours

Autor: Desiree M. Van Zomeren, V. M. M. Herben, R. Dubbelman, Jos H. Beijnen, Jan H.M. Schellens, Solange Hearn, Nadja E. Schoemaker, Wim W. ten Bokkel Huinink, Hilde Rosing

Publikováno v: Cancer chemotherapy and pharmacology. 50(1)

Purpose. The objectives of the study were to determine the pharmacokinetics and routes of excretion of topotecan following intravenous or oral administration to patients with refractory solid tumours. Methods. Patients were randomized to receive eith

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2352c320a5db8dc3286e5b89e357c918
https://pubmed.ncbi.nlm.nih.gov/12111113

Zobrazit plný text záznamu

High-performance liquid chromatographic analysis for the determination of a novel polymer-bound camptothecin derivative (MAG-camptothecin) and free camptothecin in human plasma

Autor: Nadja E. Schoemaker, Jos H. Beijnen, Daniela Fraier, Sindy Jansen, Hilde Rosing, Enrico Frigerio, Jan H.M. Schellens

Publikováno v: Journal of chromatography. B, Biomedical sciences and applications. 763(1-2)

A selective HPLC assay is described for the determination of free and total (free plus polymer-bound) camptothecin (CPT) in human plasma after administration of the anti-tumor drug MAG-CPT (polymer bound camptothecin). Total CPT levels were determine

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2bfae2df4952df96a7617bd301211de
https://pubmed.ncbi.nlm.nih.gov/11710576

Zobrazit plný text záznamu

Randomized phase I and pharmacological study of weekly or 2-weekly gemcitabine and cisplatin in advanced non-small cell lung cancer

Autor: N Van Zandwijk, Nadja E. Schoemaker, Dick Pluim, P. Baas, M. Crul, J.H.M. Schellens, Rolf W. Sparidans, J. H. Beijnen

Publikováno v: British Journal of Clinical Pharmacology. 54:554-555

Cisplatin (cis) and gemcitabine (gem) are cytotoxic drugs that have shown synergism in non-small cell lung cancer (NSCLC). The standard schedule doses gem weekly and cis once every 4 weeks. We believe that increasing the dose-intensity of cis could f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4f3aa3c1ae21de76d50c73cac12d3bd
https://doi.org/10.1046/j.1365-2125.2002.t01-8-01714.x

Zobrazit plný text záznamu

Phase I and Pharmacokinetic Study of a Daily Times 5 Short Intravenous Infusion Schedule of 9-Aminocamptothecin in a Colloidal Dispersion Formulation in Patients With Advanced Solid Tumors

Autor: Margaret Schot, V. M. M. Herben, Jan Lieverst, Maria Grazia Porro, Michel J.X. Hillebrand, Nadja E. Schoemaker, Jan H.M. Schellens, Wim W. ten Bokkel Huinink, Jos H. Beijnen, Roel van Gijn

Publikováno v: Journal of Clinical Oncology. 17:1906-1906

PURPOSE: To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetics of 9-aminocamptothecin (9-AC) in a colloidal dispersion (CD) formulation administered as a 30-minute intravenous (IV) infusion over 5 consecu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87d7627820aacdc76fb517422294e257
https://doi.org/10.1200/jco.1999.17.6.1906

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání